Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPSIS: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

NCT05665387 is registered in ClinicalTrials.gov with Santen Inc. as lead sponsor.

NCT NCT05665387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPSIS: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
Lead sponsor
Santen Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 22, 2022
Completion date
July 27, 2023
Enrollment
79 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

presbyopia